WEBULL
WebtradeDownload

Is Aevis Victoria (SWX:AEVS) Still Undervalued After Closing At CHF 14.90?

Simply Wall St · 1d ago

Aevis Victoria (SWX:AEVS) has drawn fresh attention after its shares closed at CHF 14.90. This has left investors weighing how recent price moves align with the group’s healthcare, hospitality and real estate footprint in Switzerland.

The recent move to CHF 14.90 caps a strong run, with a 30-day share price return of 16.86% and a 90-day gain of 21.63%. Aevis Victoria’s 1-year total shareholder return of 11.19% contrasts with a 3-year total shareholder return that declined 18.58%, hinting that momentum has picked up only more recently.

Scan how Aevis Victoria compares with other Swiss-listed operators by reviewing our hand picked list of solid balance sheet and fundamentals (206 results) that could appeal to investors watching this latest share price move.

Aevis Victoria now trades at CHF 14.90 while analyst and model estimates point higher and lower. Is this latest swing a stretch or still inside fair value territory?

Most Popular Narrative: 12% Undervalued

Aevis Victoria’s most followed valuation story pegs fair value at CHF 17.00, which sits above the last close at CHF 14.90 and frames the latest move as still leaving some upside on the table according to that view.

The integrated care and VIVA capitation model sits directly on top of an aging population and rising chronic disease burden, and early evidence of cost optimization in existing regions suggests that growing membership beyond the breakeven level could support higher revenue visibility and contribute to improved earnings.

See why 1 investors see Aevis Victoria as 12% undervalued.

Result: Fair Value of CHF 17.00 (UNDERVALUED)

Still, the Aevis Victoria story relies heavily on lifting margins at acquired hospitals and improving low margin ambulatory care, and setbacks in these areas could quickly weaken that 12% undervaluation case.

Find out about the key risks to this Aevis Victoria narrative.

Another View on Aevis Victoria’s Valuation

The story changes when you look at Aevis Victoria through its P/S ratio. The shares trade on 1.2x sales, compared with 0.8x for the wider European healthcare group and a fair ratio of 0.8x, which points to valuation risk if sentiment cools or growth assumptions soften.

To see how this price stacks up against the underlying numbers, review the valuation breakdown built around this sales multiple, then pressure test your own expectations against it with See what the numbers say about this price — find out in our valuation breakdown..

SWX:AEVS P/S Ratio as at Oct 2026
SWX:AEVS P/S Ratio as at Oct 2026

Next Steps

Feeling mixed about Aevis Victoria after all this valuation noise? Move quickly from headline narratives to hard numbers by checking the 2 important warning signs.

Looking for more Aevis Victoria sized ideas?

If Aevis Victoria has you thinking harder about valuation and risk, do not stop here. Filter fresh opportunities now or you will leave potential ideas unseen.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.